# Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes

> **NCT00568984** · PHASE4 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 324 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** repaglinide
- **DRUG:** metformin
- **DRUG:** glicazide

## Key facts

- **NCT ID:** NCT00568984
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11-21
- **Primary completion:** 2003-11-10
- **Final completion:** 2003-11-10
- **Target enrollment:** 324 (ACTUAL)
- **Last updated:** 2017-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00568984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00568984, "Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00568984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*